Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

NEPH vs FELE vs GWW vs CNMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NEPH
Nephros, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$38M
5Y Perf.-54.9%
FELE
Franklin Electric Co., Inc.

Industrial - Machinery

IndustrialsNASDAQ • US
Market Cap$4.39B
5Y Perf.+95.9%
GWW
W.W. Grainger, Inc.

Industrial - Distribution

IndustrialsNYSE • US
Market Cap$58.39B
5Y Perf.+298.5%
CNMD
CONMED Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$1.13B
5Y Perf.-49.9%

NEPH vs FELE vs GWW vs CNMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NEPH logoNEPH
FELE logoFELE
GWW logoGWW
CNMD logoCNMD
IndustryMedical - Instruments & SuppliesIndustrial - MachineryIndustrial - DistributionMedical - Devices
Market Cap$38M$4.39B$58.39B$1.13B
Revenue (TTM)$19M$2.18B$18.38B$1.37B
Net Income (TTM)$776K$150M$1.78B$55M
Gross Margin59.2%35.2%39.2%53.6%
Operating Margin3.5%12.6%14.2%11.3%
Forward P/E32.0x21.6x27.7x8.4x
Total Debt$1M$280M$3.16B$835M
Cash & Equiv.$5M$100M$585M$41M

NEPH vs FELE vs GWW vs CNMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NEPH
FELE
GWW
CNMD
StockMay 20May 26Return
Nephros, Inc. (NEPH)10045.1-54.9%
Franklin Electric C… (FELE)100195.9+95.9%
W.W. Grainger, Inc. (GWW)100398.5+298.5%
CONMED Corporation (CNMD)10050.1-49.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: NEPH vs FELE vs GWW vs CNMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NEPH leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. W.W. Grainger, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. CNMD also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
NEPH
Nephros, Inc.
The Growth Play

NEPH carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 32.7%, EPS growth -10.1%, 3Y rev CAGR 23.5%
  • Lower volatility, beta 0.58, Low D/E 10.4%, current ratio 4.06x
  • Beta 0.58, current ratio 4.06x
  • 32.7% revenue growth vs GWW's 4.5%
Best for: growth exposure and sleep-well-at-night
FELE
Franklin Electric Co., Inc.
The Secondary Option

FELE lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: industrials exposure
GWW
W.W. Grainger, Inc.
The Income Pick

GWW is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 37 yrs, beta 0.87, yield 0.8%
  • 462.8% 10Y total return vs FELE's 229.5%
  • 9.7% margin vs CNMD's 4.0%
  • 19.7% ROA vs CNMD's 2.4%, ROIC 32.1% vs 5.8%
Best for: income & stability and long-term compounding
CNMD
CONMED Corporation
The Value Pick

CNMD is the clearest fit if your priority is valuation efficiency.

  • PEG 0.23 vs FELE's 2.48
  • Lower P/E (8.4x vs 27.7x), PEG 0.23 vs 1.24
  • 2.2% yield, 2-year raise streak, vs GWW's 0.8%, (1 stock pays no dividend)
Best for: valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthNEPH logoNEPH32.7% revenue growth vs GWW's 4.5%
ValueCNMD logoCNMDLower P/E (8.4x vs 27.7x), PEG 0.23 vs 1.24
Quality / MarginsGWW logoGWW9.7% margin vs CNMD's 4.0%
Stability / SafetyNEPH logoNEPHBeta 0.58 vs CNMD's 1.32, lower leverage
DividendsCNMD logoCNMD2.2% yield, 2-year raise streak, vs GWW's 0.8%, (1 stock pays no dividend)
Momentum (1Y)NEPH logoNEPH+76.9% vs CNMD's -35.7%
Efficiency (ROA)GWW logoGWW19.7% ROA vs CNMD's 2.4%, ROIC 32.1% vs 5.8%

NEPH vs FELE vs GWW vs CNMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NEPHNephros, Inc.
FY 2025
Royalty and Other Revenues
50.5%$555,000
Service
47.3%$520,000
Other Revenue
2.2%$24,000
FELEFranklin Electric Co., Inc.
FY 2025
Water Systems
55.7%$1.3B
Distribution
31.1%$701M
Energy Systems
13.3%$299M
GWWW.W. Grainger, Inc.
FY 2025
High-Touch Solutions (N.A.)
79.4%$14.0B
Endless Assortment
20.6%$3.6B
CNMDCONMED Corporation
FY 2025
General Surgery
58.2%$800M
Orthopedic Surgery
41.8%$575M

NEPH vs FELE vs GWW vs CNMD — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGWWLAGGINGFELE

Income & Cash Flow (Last 12 Months)

GWW leads this category, winning 3 of 6 comparable metrics.

GWW is the larger business by revenue, generating $18.4B annually — 961.0x NEPH's $19M. GWW is the more profitable business, keeping 9.7% of every revenue dollar as net income compared to CNMD's 4.0%. On growth, GWW holds the edge at +10.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNEPH logoNEPHNephros, Inc.FELE logoFELEFranklin Electric…GWW logoGWWW.W. Grainger, In…CNMD logoCNMDCONMED Corporation
RevenueTrailing 12 months$19M$2.2B$18.4B$1.4B
EBITDAEarnings before interest/tax$806,000$322M$2.9B$219M
Net IncomeAfter-tax profit$776,000$150M$1.8B$55M
Free Cash FlowCash after capex-$348,000$169M$1.4B$124M
Gross MarginGross profit ÷ Revenue+59.2%+35.2%+39.2%+53.6%
Operating MarginEBIT ÷ Revenue+3.5%+12.6%+14.2%+11.3%
Net MarginNet income ÷ Revenue+4.1%+6.9%+9.7%+4.0%
FCF MarginFCF ÷ Revenue-1.8%+7.8%+7.5%+9.0%
Rev. Growth (YoY)Latest quarter vs prior year+6.9%+9.9%+10.1%-0.7%
EPS Growth (YoY)Latest quarter vs prior year-81.0%+13.4%+18.2%+136.8%
GWW leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

CNMD leads this category, winning 7 of 7 comparable metrics.

At 24.3x trailing earnings, CNMD trades at a 30% valuation discount to GWW's 34.9x P/E. Adjusting for growth (PEG ratio), CNMD offers better value at 0.67x vs FELE's 3.51x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNEPH logoNEPHNephros, Inc.FELE logoFELEFranklin Electric…GWW logoGWWW.W. Grainger, In…CNMD logoCNMDCONMED Corporation
Market CapShares × price$38M$4.4B$58.4B$1.1B
Enterprise ValueMkt cap + debt − cash$34M$4.6B$61.0B$1.9B
Trailing P/EPrice ÷ TTM EPS32.00x30.57x34.85x24.34x
Forward P/EPrice ÷ next-FY EPS est.21.64x27.70x8.41x
PEG RatioP/E ÷ EPS growth rate3.51x1.56x0.67x
EV / EBITDAEnterprise value multiple26.34x13.74x20.70x9.96x
Price / SalesMarket cap ÷ Revenue2.03x2.06x3.25x0.82x
Price / BookPrice ÷ Book value/share3.78x3.39x14.30x1.11x
Price / FCFMarket cap ÷ FCF23.23x22.67x43.87x7.51x
CNMD leads this category, winning 7 of 7 comparable metrics.

Profitability & Efficiency

GWW leads this category, winning 5 of 9 comparable metrics.

GWW delivers a 43.1% return on equity — every $100 of shareholder capital generates $43 in annual profit, vs $5 for CNMD. NEPH carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNMD's 0.81x. On the Piotroski fundamental quality scale (0–9), GWW scores 8/9 vs CNMD's 5/9, reflecting strong financial health.

MetricNEPH logoNEPHNephros, Inc.FELE logoFELEFranklin Electric…GWW logoGWWW.W. Grainger, In…CNMD logoCNMDCONMED Corporation
ROE (TTM)Return on equity+7.7%+11.4%+43.1%+5.4%
ROA (TTM)Return on assets+5.9%+7.6%+19.7%+2.4%
ROICReturn on invested capital+14.2%+14.7%+32.1%+5.8%
ROCEReturn on capital employed+11.2%+18.1%+39.7%+7.0%
Piotroski ScoreFundamental quality 0–96585
Debt / EquityFinancial leverage0.10x0.21x0.76x0.81x
Net DebtTotal debt minus cash-$4M$181M$2.6B$794M
Cash & Equiv.Liquid assets$5M$100M$585M$41M
Total DebtShort + long-term debt$1M$280M$3.2B$835M
Interest CoverageEBIT ÷ Interest expense588.00x24.75x32.42x5.20x
GWW leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — NEPH and GWW each lead in 3 of 6 comparable metrics.

A $10,000 investment in GWW five years ago would be worth $26,784 today (with dividends reinvested), compared to $2,818 for CNMD. Over the past 12 months, NEPH leads with a +76.9% total return vs CNMD's -35.7%. The 3-year compound annual growth rate (CAGR) favors NEPH at 33.2% vs CNMD's -31.9% — a key indicator of consistent wealth creation.

MetricNEPH logoNEPHNephros, Inc.FELE logoFELEFranklin Electric…GWW logoGWWW.W. Grainger, In…CNMD logoCNMDCONMED Corporation
YTD ReturnYear-to-date-25.9%+3.0%+23.1%-9.3%
1-Year ReturnPast 12 months+76.9%+14.9%+18.8%-35.7%
3-Year ReturnCumulative with dividends+136.2%+9.4%+85.3%-68.4%
5-Year ReturnCumulative with dividends-54.4%+21.6%+167.8%-71.8%
10-Year ReturnCumulative with dividends+11.7%+229.5%+462.8%+3.5%
CAGR (3Y)Annualised 3-year return+33.2%+3.0%+22.8%-31.9%
Evenly matched — NEPH and GWW each lead in 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NEPH and GWW each lead in 1 of 2 comparable metrics.

NEPH is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than CNMD's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GWW currently trades 95.9% from its 52-week high vs NEPH's 54.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNEPH logoNEPHNephros, Inc.FELE logoFELEFranklin Electric…GWW logoGWWW.W. Grainger, In…CNMD logoCNMDCONMED Corporation
Beta (5Y)Sensitivity to S&P 5000.58x0.89x0.87x1.32x
52-Week HighHighest price in past year$6.42$111.53$1286.56$61.08
52-Week LowLowest price in past year$1.88$83.42$906.52$33.21
% of 52W HighCurrent price vs 52-week peak+54.8%+89.1%+95.9%+60.2%
RSI (14)Momentum oscillator 0–10054.651.469.653.1
Avg Volume (50D)Average daily shares traded35K275K237K403K
Evenly matched — NEPH and GWW each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — GWW and CNMD each lead in 1 of 2 comparable metrics.

Analyst consensus: FELE as "Hold", GWW as "Hold", CNMD as "Hold". Consensus price targets imply 112.2% upside for CNMD (target: $78) vs -3.3% for GWW (target: $1193). For income investors, CNMD offers the higher dividend yield at 2.16% vs GWW's 0.79%.

MetricNEPH logoNEPHNephros, Inc.FELE logoFELEFranklin Electric…GWW logoGWWW.W. Grainger, In…CNMD logoCNMDCONMED Corporation
Analyst RatingConsensus buy/hold/sellHoldHoldHold
Price TargetConsensus 12-month target$100.00$1193.14$78.00
# AnalystsCovering analysts113821
Dividend YieldAnnual dividend ÷ price+1.1%+0.8%+2.2%
Dividend StreakConsecutive years of raises032372
Dividend / ShareAnnual DPS$1.11$9.73$0.79
Buyback YieldShare repurchases ÷ mkt cap0.0%+3.8%+1.8%0.0%
Evenly matched — GWW and CNMD each lead in 1 of 2 comparable metrics.
Key Takeaway

GWW leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CNMD leads in 1 (Valuation Metrics). 3 tied.

Best OverallW.W. Grainger, Inc. (GWW)Leads 2 of 6 categories
Loading custom metrics...

NEPH vs FELE vs GWW vs CNMD: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NEPH or FELE or GWW or CNMD a better buy right now?

For growth investors, Nephros, Inc.

(NEPH) is the stronger pick with 32. 7% revenue growth year-over-year, versus 4. 5% for W. W. Grainger, Inc. (GWW). CONMED Corporation (CNMD) offers the better valuation at 24. 3x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate Franklin Electric Co. , Inc. (FELE) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NEPH or FELE or GWW or CNMD?

On trailing P/E, CONMED Corporation (CNMD) is the cheapest at 24.

3x versus W. W. Grainger, Inc. at 34. 9x. On forward P/E, CONMED Corporation is actually cheaper at 8. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CONMED Corporation wins at 0. 23x versus Franklin Electric Co. , Inc. 's 2. 48x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — NEPH or FELE or GWW or CNMD?

Over the past 5 years, W.

W. Grainger, Inc. (GWW) delivered a total return of +167. 8%, compared to -71. 8% for CONMED Corporation (CNMD). Over 10 years, the gap is even starker: GWW returned +462. 8% versus CNMD's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NEPH or FELE or GWW or CNMD?

By beta (market sensitivity over 5 years), Nephros, Inc.

(NEPH) is the lower-risk stock at 0. 58β versus CONMED Corporation's 1. 32β — meaning CNMD is approximately 128% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 81% for CONMED Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — NEPH or FELE or GWW or CNMD?

By revenue growth (latest reported year), Nephros, Inc.

(NEPH) is pulling ahead at 32. 7% versus 4. 5% for W. W. Grainger, Inc. (GWW). On earnings-per-share growth, the picture is similar: W. W. Grainger, Inc. grew EPS -8. 6% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NEPH or FELE or GWW or CNMD?

W.

W. Grainger, Inc. (GWW) is the more profitable company, earning 9. 5% net margin versus 3. 4% for CONMED Corporation — meaning it keeps 9. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GWW leads at 15. 0% versus 6. 1% for NEPH. At the gross margin level — before operating expenses — NEPH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NEPH or FELE or GWW or CNMD more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, CONMED Corporation (CNMD) is the more undervalued stock at a PEG of 0. 23x versus Franklin Electric Co. , Inc. 's 2. 48x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CONMED Corporation (CNMD) trades at 8. 4x forward P/E versus 27. 7x for W. W. Grainger, Inc. — 19. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNMD: 112. 2% to $78. 00.

08

Which pays a better dividend — NEPH or FELE or GWW or CNMD?

In this comparison, CNMD (2.

2% yield), FELE (1. 1% yield), GWW (0. 8% yield) pay a dividend. NEPH does not pay a meaningful dividend and should not be held primarily for income.

09

Is NEPH or FELE or GWW or CNMD better for a retirement portfolio?

For long-horizon retirement investors, W.

W. Grainger, Inc. (GWW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 0. 8% yield, +462. 8% 10Y return). Both have compounded well over 10 years (GWW: +462. 8%, CNMD: +3. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NEPH and FELE and GWW and CNMD?

These companies operate in different sectors (NEPH (Healthcare) and FELE (Industrials) and GWW (Industrials) and CNMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEPH is a small-cap high-growth stock; FELE is a small-cap quality compounder stock; GWW is a mid-cap quality compounder stock; CNMD is a small-cap quality compounder stock. FELE, GWW, CNMD pay a dividend while NEPH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

NEPH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 35%
Run This Screen
Stocks Like

FELE

Stable Dividend Mega-Cap

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

GWW

Stable Dividend Mega-Cap

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

CNMD

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 32%
  • Dividend Yield > 0.8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform NEPH and FELE and GWW and CNMD on the metrics below

Revenue Growth>
%
(NEPH: 6.9% · FELE: 9.9%)
Net Margin>
%
(NEPH: 4.1% · FELE: 6.9%)
P/E Ratio<
x
(NEPH: 32.0x · FELE: 30.6x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.